| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 93 | 11.6x | 17.8x | Top tier | |
Growth | 50 | 7.8% | 7.1% | Around median | |
Quality | 68 | 11.9% | 4.5% | Top tier | |
Safety | 65 | 1.8x | 2.6x | Around median | |
Capital Return | 51 | 2.19% | 2.12% | Around median | |
Momentum | 56 | -7.5% | 2.9% | Around median | |
Sentiment | 43 | 15 | 3 | Around median |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
The Cigna Group operates through two primary revenue and earnings engines. Evernorth Health Services provides specialty pharmacy services through Accredo, pharmacy benefit management, care programs, and hospital and health system solutions through Shields Health Solutions, Verity, and Carepath; while Cigna Healthcare focuses on employer-sponsored healthcare plans, stop-loss insurance, supplemental health benefits, and international health businesses. Growth depends on increased specialty drug utilization, management of drug and care costs, and employer acquisition and contract retention.
In fiscal Q2 2026, total revenue reached $71.7 billion, gross profit according to EDGAR data was approximately $15.0 billion, net income was $1.7 billion, and earnings per share were $6.29; equivalent to a gross margin of approximately 20.9% and a net margin of approximately 2.4%. On the adjusted basis management uses to measure performance, the company reported after-tax earnings of $2.1 billion and adjusted earnings per share of $7.78, after accounting for after-tax special items of $153 million, or $0.58 per share.
Evernorth represented the largest share of activity in fiscal Q2 2026, with revenue of $61.5 billion, up 6% year over year, and adjusted pre-tax earnings of $1.7 billion. Cigna Healthcare generated revenue of $11.8 billion, up 10%, and adjusted pre-tax earnings of $1.3 billion, while Specialty & Care Services pre-tax earnings rose 22% to $1.1 billion, compared with $609 million for Pharmacy Benefit Services, which declined from the prior year.
The analyst consensus rates CI as a Buy, with an average price target of $338.33 and a wide range of $302 to $400; the average is approximately 7% above the 52-week range high of $315.47. This positive view is set against a wide annual range of $239.51 to $315.47, reflecting the market’s balance between the raised fiscal 2026 earnings outlook and the strength of specialty services on one hand, and elevated care costs, the Pharmacy Benefit Services transition, and slowing GLP-1 growth on the other.
Figures in the text are as of 2026-08-27; the live price is shown at the top of the page.
The Cigna Group generated approximately $71.7 billion in revenue in fiscal Q2 2026, with adjusted earnings per share of $7.78. Specialty & Care Services led performance with 22% year-over-year growth in adjusted pre-tax earnings to $1.1 billion, supported by specialty utilization, biosimilars, and specialty generics. Cigna Healthcare also recorded 17% year-over-year growth in adjusted pre-tax earnings, benefiting from the performance of the employer business and lower-than-expected outpatient surgery expenses.
Evernorth generated revenue of $61.5 billion and adjusted pre-tax earnings of $1.7 billion in fiscal Q2 2026. Its assets include Accredo, pharmacy benefit management services, and Shields Health Solutions, Verity, and Carepath solutions for hospitals and health systems. Accredo provides access to more than 330 limited-distribution drugs, while Shields serves more than 80 health systems and over 1,000 hospitals across 50 states.
Signature is a rebate-free pharmacy benefits model designed to simplify pricing and shift client relationships to transparent, fee-based arrangements. Cigna will first offer it to Cigna Healthcare’s fully insured plans in fiscal 2027, then plans to expand it in 2028. Management expects its margins to reach approximately 4% at maturity, but anticipates continued transition investments in fiscal 2027 at a level similar to fiscal 2026 before they gradually decline.
Automated analysis for informational purposes only — not investment advice.
In fiscal Q2 2026, the company recorded slower GLP-1 prescription growth, with a slight decline in coverage and slower utilization compared with previously elevated levels. Management expects this trend to continue through the remainder of fiscal 2026, creating modest pressure on Pharmacy Benefit Services. Within the Cigna Healthcare portfolio, only 15% to 20% of the business base covers GLP-1 drugs for weight management, so management described the direct financial impact there as relatively limited.
Cigna raised its adjusted earnings-per-share outlook for fiscal 2026 to at least $30.45 following the second-quarter results. It maintained its outlook for Evernorth adjusted pre-tax earnings at no less than $6.9 billion and raised its Cigna Healthcare outlook to at least $4.55 billion. It also expects free operating cash flow of approximately $9 billion, with most of it concentrated in the second half of fiscal 2026, and aims to end the year with a debt-to-capital ratio closer to 40%, compared with 42.8% on June 30, 2026.
